Englander Institute for Precision Medicine

Publications

Found 692 results
Author Title [ Type(Desc)] Year
Journal Article
Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Vélez NEFélix, Abeles EB, Allam M, Hu T et al..  2023.  Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.. Nat Mater. 22(4):511-523.
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.
Laimighofer M, Lickert R, Fuerst R, Theis FJ, Winkler C, Bonifacio E, Ziegler A-G, Krumsiek J.  2019.  Common patterns of gene regulation associated with Cesarean section and the development of islet autoimmunity - indications of immune cell activation.. Sci Rep. 9(1):6250.
Batra R, Krumsiek J, Wang X, Allen M, Blach C, Kastenmüller G, Arnold M, Ertekin-Taner N, Kaddurah-Daouk RF.  2023.  Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy.. medRxiv.
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A et al..  2022.  Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. J Pathol. 257(3):274-284.
Bauer A, Zierer A, Gieger C, Buyukozkan M, Müller-Nurasyid M, Grallert H, Meisinger C, Strauch K, Prokisch H, Roden M et al..  2021.  Comparison of genetic risk prediction models to improve prediction of coronary heart disease in two large cohorts of the MONICA/KORA study.. Genet Epidemiol. 45(6):633-650.
Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O et al..  2019.  Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.. Theranostics. 9(2):540-553.
Bhinder B, Elemento O.  2020.  Computational methods in tumor immunology.. Methods Enzymol. 636:209-259.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez ABuqué, Chan TA, Coukos G, Demaria S, Deutsch E et al..  2020.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.. J Immunother Cancer. 8(1)
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2021.  Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.. Eur J Cancer. 159:237-246.
Kadri S, Sboner A, Sigaras A, Roy S.  2022.  Containers in Bioinformatics: Applications, Practical Considerations, and Best Practices in Molecular Pathology.. J Mol Diagn. 24(5):442-454.
Marchi S, Morroni G, Pinton P, Galluzzi L.  2022.  Control of host mitochondria by bacterial pathogens.. Trends Microbiol. 30(5):452-465.
Pilones KA, Hensler M, Daviaud C, Kraynak J, Fucikova J, Galluzzi L, Demaria S, Formenti SC.  2020.  Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.. Oncoimmunology. 9(1):1830524.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Naqvi SArsalan, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R et al..  2023.  Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.. Eur Urol Oncol.
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A et al..  2024.  Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.. bioRxiv.
Meleshko D, Hajirasouliha I, Korobeynikov A.  2021.  coronaSPAdes: from biosynthetic gene clusters to RNA viral assemblies.. Bioinformatics. 38(1):1-8.
Huang SH, Sartorello G, Shen P-T, Xu C, Elemento O, Shvets G.  2023.  Correction: Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.. Lab Chip. 23(17):3893.
Popic V, Rohlicek C, Cunial F, Hajirasouliha I, Meleshko D, Garimella K, Maheshwari A.  2023.  Cue: a deep-learning framework for structural variant discovery and genotyping.. Nat Methods. 20(4):559-568.
Punjani N, Kang C, Lamb DJ, Schlegel PN.  2021.  Current updates and future perspectives in the evaluation of azoospermia: A systematic review.. Arab J Urol. 19(3):206-214.
Goltz D, Holmes EEva, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G et al..  2016.  CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.. Oncotarget. 7(33):53309-53320.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..  2024.  Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Álvarez-Abril B, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Buqué A, Galluzzi L et al..  2022.  Cytofluorometric assessment of acute cell death responses driven by radiation therapy.. Methods Cell Biol. 172:17-36.
Jiménez-Cortegana C, Klapp V, Bloy N, Galassi C, Sato A, Yamazaki T, Buqué A, Galluzzi L, Petroni G.  2022.  Cytofluorometric assessment of cell cycle progression in irradiated cells.. Methods Cell Biol. 172:1-16.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B.  2022.  Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.. Future Oncol. 18(21):2585-2597.